Analytical Data
-
基因名
ccdA
- Application
-
别名
ccdA；CCDC10；CSDUFD1；FSD1CL；FSD1-like Protein
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q46995
-
表达区间
1-72aa
-
氨基酸序列
MKQRITVAGDSDNYQLLKAYDVNISGLVSTPMQNEARRLRPERWKVANQEGMAEVARFIEMNGSFADENRDW
-
分子量
15.6 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The research on the recombinant protein CCDAs (cystathionine gamma-lyase-derived antibiotic) has gained considerable attention in the field of microbiology and pharmacology due to its potential therapeutic applications. CCDAs are derived from the cystathionine gamma-lyase enzyme, which plays a critical role in the transsulfuration pathway, crucial for amino acid metabolism and the synthesis of bioactive compounds. The recombinant production of CCDAs allows for high-throughput generation and purification, facilitating the study of their structure-function relationships. These proteins have shown promise in eliciting antimicrobial and antifungal activities, making them candidates for the development of novel antibiotics in response to rising antibiotic resistance. Moreover, understanding the mechanism of action of CCDAs can lead to the identification of new drug targets and the design of more effective therapeutic agents. Researchers are also exploring their synergistic effects with existing antibiotics, which could enhance the efficacy of treatment regimens. Overall, the investigation of recombinant CCDAs not only contributes to our understanding of microbial metabolism but also represents a significant stride towards innovative approaches in combating infectious diseases.
